Glenmark Pharmaceuticals Limited (GLENMARK)
Press Release
Ichnos Glenmark Innovation to present updated Phase 1 clinical data for ISB 2001 in relapsed/refractory multiple myeloma at 68th ASH Annual Meeting on Dec 12, 2026.
- ISB 2001 is a first- and only-in-class CD38 × BCMA × CD3 trispecific T-cell engager.
- Updated data include longer follow-up from dose-escalation and early dose-expansion results.
- Presentation by Dr. Binod Dhakal at 4-4:15pm CST, New Orleans.
- IGI and AbbVie advancing ISB 2001 as potential new treatment option for RRMM.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 GLENMARK — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add GLENMARK to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Glenmark Pharmaceuticals Limited
Important.
The summary above is generated automatically from Glenmark Pharmaceuticals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.